Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Michele Baccarani, MD, Brian J. Druker, MD, Jorge Cortes-Franco, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Fabrizio Pane, Susan Branford, PhD, Yu Jin, MSc, Tillmann Krahnke, PhD, Marc Rudoltz, MD, Jerald P. Radich, MD, François Guilhot, MD

Blood (2009) 114 (22): 337.

https://doi.org/10.1182/blood.V114.22.337.337

Published: 2009

Journal Articles

A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study

Jorge Cortes, MD, Michele Baccarani, MD, François Guilhot, MD, Brian J. Druker, MD, Susan Branford, PhD, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Marc Rudoltz, MD, Richard Yu, LaTonya Collins, RN, BSN, Tillmann Krahnke, PhD, Jerald P. Radich, MD, Timothy P Hughes, MD

Blood (2008) 112 (11): 335.

https://doi.org/10.1182/blood.V112.11.335.335

Published: 2008

Journal Articles

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.

Vi j ay Modur, MD, PhD, Dean C Bottino, PhD, Susan Branford, PhD, Tillmann Krahnke, PhD, Fabrizio Pane, MD, Marc Rudoltz, MD, Yu Jin, Timothy P Hughes, MD, Dong-Wook Kim, MD, PhD, Jerald Radich, MD, J. Carl Barrett, PhD

Blood (2008) 112 (11): 2124.

https://doi.org/10.1182/blood.V112.11.2124.2124

Published: 2008

Journal Articles

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson, Brian J. Druker, Francois Guilhot, Stephen G. O'Brien, Gilles J. Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang

Blood (2008) 111 (8): 4022–4028.

https://doi.org/10.1182/blood-2007-10-116475

Published: 2008

Includes: Supplemental data

Journal Articles

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Andreas Hochhaus, Brian Druker, Charles Sawyers, Francois Guilhot, Charles A. Schiffer, Jorge Cortes, Dietger W. Niederwieser, Carlo Gambacorti-Passerini, Richard M. Stone, John Goldman, Thomas Fischer, Stephen G. O'Brien, Jose J. Reiffers, Manisha Mone, Tillmann Krahnke, Moshe Talpaz, Hagop M. Kantarjian

Blood (2008) 111 (3): 1039–1043.

https://doi.org/10.1182/blood-2007-07-103523

Published: 2008

Journal Articles

Imatinib Dose Escalation Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Hagop M. Kantarjian, MD, Brian J. Druker, MD, Francois Guilhot, MD, Jorge Cortes, MD, Stephen G. O’Brien, MD, PhD, Tillmann Krahnke, Richard A. Larson, MD

Blood (2007) 110 (11): 1047.

https://doi.org/10.1182/blood.V110.11.1047.1047

Published: 2007

Journal Articles

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Lydia Roy, Joëlle Guilhot, Tillmann Krahnke, Agnès Guerci-Bresler, Brian J. Druker, Richard A. Larson, Steve O'Brien, Charlene So, Giorgio Massimini, François Guilhot

Blood (2006) 108 (5): 1478–1484.

https://doi.org/10.1182/blood-2006-02-001495

Published: 2006

Journal Articles

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Francois Guilhot, MD, Lydia Roy, MD, Joelle Guilhot, BS, Tillmann Krahnke, BSR, Agnes Guerci, MD, Brian Druker, MD, Richard Larson, MD, Steve O’Brien, MD, Charlene So, PharmD, Giorgio Massimini, MD

Blood (2005) 106 (11): 165.

https://doi.org/10.1182/blood.V106.11.165.165

Published: 2005

Journal Articles

Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α.

Carlo Gambacorti, Moshe Talpaz, Charles L. Sawyers, Brian J. Druker, Andreas Hochhaus, Charles A. Schiffer, Francois Guilhot, Dietger W. Niederwieser, Richard M. Stone, John M. Goldman, Manisha Mone, Tillmann Krahnke, Insa Gathmann, Hagop M. Kantarjian

Blood (2005) 106 (11): 1089.

https://doi.org/10.1182/blood.V106.11.1089.1089

Published: 2005

NARROW

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Imatinib Dose Escalation Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only